Financial Counselors Inc. reduced its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 1.1% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 16,150 shares of the biotechnology company’s stock after selling 177 shares during the period. Financial Counselors Inc.’s holdings in Grifols, were worth $341,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. AKO Capital LLP increased its holdings in Grifols, by 5.7% during the 2nd quarter. AKO Capital LLP now owns 12,341,363 shares of the biotechnology company’s stock worth $9,335,000 after purchasing an additional 667,174 shares in the last quarter. FMR LLC increased its holdings in Grifols, by 52.6% during the 1st quarter. FMR LLC now owns 6,352,581 shares of the biotechnology company’s stock worth $119,905,000 after purchasing an additional 2,189,431 shares in the last quarter. Pictet Asset Management Ltd. increased its holdings in Grifols, by 7.8% during the 2nd quarter. Pictet Asset Management Ltd. now owns 5,409,186 shares of the biotechnology company’s stock worth $116,081,000 after purchasing an additional 390,486 shares in the last quarter. FIL Ltd increased its holdings in Grifols, by 0.4% during the 1st quarter. FIL Ltd now owns 3,689,737 shares of the biotechnology company’s stock worth $69,644,000 after purchasing an additional 15,142 shares in the last quarter. Finally, Alliancebernstein L.P. increased its holdings in Grifols, by 8.1% during the 2nd quarter. Alliancebernstein L.P. now owns 3,067,089 shares of the biotechnology company’s stock worth $64,808,000 after purchasing an additional 229,425 shares in the last quarter. 21.93% of the stock is owned by hedge funds and other institutional investors.

Grifols, S.A. (NASDAQ GRFS) opened at 21.70 on Thursday. The company has a market capitalization of $29.65 billion, a price-to-earnings ratio of 44.33 and a beta of 1.00. The stock has a 50 day moving average price of $20.58 and a 200 day moving average price of $20.26. Grifols, S.A. has a 12-month low of $14.27 and a 12-month high of $22.83.

GRFS has been the subject of several recent analyst reports. Zacks Investment Research raised Grifols, from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a report on Tuesday, July 4th. Bank of America Corporation reaffirmed a “buy” rating on shares of Grifols, in a report on Tuesday, July 4th. BidaskClub raised Grifols, from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Finally, Goldman Sachs Group, Inc. (The) lowered Grifols, from a “buy” rating to a “neutral” rating in a report on Friday, June 30th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $24.00.

ILLEGAL ACTIVITY NOTICE: “Financial Counselors Inc. Sells 177 Shares of Grifols, S.A. (GRFS)” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/14/financial-counselors-inc-sells-177-shares-of-grifols-s-a-grfs.html.

Grifols, Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS).

Institutional Ownership by Quarter for Grifols, (NASDAQ:GRFS)

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.